The panel discusses the current status of using PD-L1 as a predictive biomarker for anti–PD-1 therapy. The hope is that an optimized biomarker will be sorted out now that the drugs are becoming available for patients.
- Is the PD-L1 Biomarker Ready for Prime Time ( Download)
- Is PD-L1 really a predictive biomarker ( Download)
- Evolving Role of PD-L1 as a Biomarker ( Download)
- Immunotherapy in Oncology and the Role of the PD-L1 Biomarker ( Download)
- PD-L1 Biomarker Testing ( Download)
- Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer ( Download)
- Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer ( Download)
- Do You Order PD-L1 Testing Before Choosing an Immune Checkpoint Inhibitor ( Download)
- Dr. Weiss on PD-L1 Biomarker in Lung Cancer ( Download)
- PD-L1 expression predicts which solid tumor patients will respond to PD-1/PD-L1 treatment ( Download)
- Dr. Brahmer Explains PD-1 and PD-L1 ( Download)
- Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance ( Download)
- Dr. Rizvi on PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer ( Download)
- Should PD-L1 Testing Be Ordered at Diagnosis or After Progression ( Download)
- Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC ( Download)
